🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against superbug strains of the bacteria, according to researchers.

An International Challenge

Cases of gonorrhoea are increasing globally, with estimates suggesting more than 82 million infections each year. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, escalating drug resistance and the highly restricted available drugs presently on offer.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Receive Clearance

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization represents a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Outcomes and Worldwide Availability

According to results detailed in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This places it at an comparable level with the typical regimen, which uses an injection and a pill. The trial included nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in many developing nations.

Medical professionals treating patients have expressed positive views. Access to a one-pill regimen of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is considered essential to reduce the burden of the illness for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.